Missing: Amira Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Amira Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Amira Pharmaceuticals Patents
Amira Pharmaceuticals has filed 1 patent.
G protein coupled receptors, Autoimmune diseases, Transcription factors, Inflammations, Hepatology
G protein coupled receptors, Autoimmune diseases, Transcription factors, Inflammations, Hepatology
Latest Amira Pharmaceuticals News
Apr 5, 2022
-- Jane Huang, M.D., appointed as independent director -- -- Sanjay Trehan joins as SVP of Business Development -- -- Gretchen Bain, Ph.D., promoted to SVP of Biology -- April 05, 2022 08:00 AM Eastern Daylight Time SAN DIEGO--( BUSINESS WIRE )--858 Therapeutics today announced the strengthening of its board of directors and leadership team in preparation for its next stage of growth. To support the advancement of 858 Therapeutics’ portfolio of small molecule therapeutics directed against oncology targets, the company has named Jane Huang, M.D., as an independent director on the company’s Board. In addition, 858 Therapeutics has appointed Sanjay Trehan as SVP of Business Development and has promoted Gretchen Bain, Ph.D., to SVP of Biology. The company debuted in September 2021 with a $60 million Series A financing led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset Management and Logos Capital. Since inception, 858 Therapeutics has progressed multiple programs in novel areas of oncology and expects to start IND-enabling work on its lead development candidate during 2022 and to start clinical activities in 2023. Dr. Huang previously was Chief Medical Officer of Hematology at BeiGene Ltd. (NASDAQ:BGNE). Prior to joining BeiGene, Dr. Huang was the Vice President and Head of Development at Acerta Pharma, where she oversaw global clinical development of the BTK inhibitor, acalabrutinib. Previously, she served as Group Medical Director at Genentech, where she spent 10 years playing a leading role in drug development programs for several molecules at all stages of development, including venetoclax and obinutuzumab. She is also adjunct clinical faculty and an attending physician in Oncology at Stanford University. Mr. Trehan joins 858 Therapeutics from Genentech, where he served as Business Development Project Leader. Prior to joining Genentech, he held business development roles of increasing responsibility at Sanofi, including Director and Head of Business Development and Licensing for Rare Diseases. During his time at Sanofi and Genentech, Mr. Trehan successfully led the evaluation and execution of numerous transactions, including product licenses, co-developments, co-promotions, drug discovery collaborations and strategic alliances. Mr. Trehan received his MBA from the MIT Sloan School of Management. “We’re excited to welcome Jane to our board. She has extensive experience in oncology drug development, and her input on our clinical development strategy will be invaluable,” said Jeffrey Stafford, Ph.D., CEO of 858 Therapeutics. “Sanjay brings a high level of business development acumen to 858 and his expertise will be essential as we expand our portfolio and advance our programs towards the clinic. The additions of Jane and Sanjay represent our commitment to support the company’s next phase of development.” In addition to the board appointment of Dr. Huang and the hiring of Mr. Trehan, 858 Therapeutics has promoted Gretchen Bain, Ph.D., to SVP of Biology. Dr. Bain cofounded the company, initially serving as VP of Biology. Prior to 858 Therapeutics, Gretchen was VP of Biology at Jecure Therapeutics, a company that was acquired by Genentech in 2018 for its NLRP3 inflammasome inhibitor program. She began her career at Merck Research Labs and transitioned into biotech in 2005 as Executive Director of Biology at Amira Pharmaceuticals. At Amira, Gretchen contributed to the development of several clinical-stage small molecule therapeutics to treat inflammation and fibrosis and directed the efforts of the LPA1 receptor antagonist program that led to the acquisition of Amira by BMS. “Gretchen has been a key member of our senior management team from the company’s inception, and her promotion recognizes her numerous scientific contributions as well as her excellence in leading our biology efforts,” said Dr. Stafford. About 858 Therapeutics 858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule therapeutics directed against novel oncology targets. Its lead programs focus on the emerging fields of RNA modulation, innate immunity and synthetic lethality, and expand upon insights from over 10 years of work by the founders at predecessor companies. 858 is headquartered in the biotech hub of San Diego, CA, with operations also in New York City, providing proximity to leading investigators and scientific talent on both coasts of the U.S. For more information, please visit www.8five8tx.com . Contacts
Amira Pharmaceuticals Frequently Asked Questions (FAQ)
When was Amira Pharmaceuticals founded?
Amira Pharmaceuticals was founded in 2005.
Where is Amira Pharmaceuticals's headquarters?
Amira Pharmaceuticals's headquarters is located at 9535 Waples Street, San Diego.
What is Amira Pharmaceuticals's latest funding round?
Amira Pharmaceuticals's latest funding round is Acquired.
How much did Amira Pharmaceuticals raise?
Amira Pharmaceuticals raised a total of $40M.
Who are the investors of Amira Pharmaceuticals?
Investors of Amira Pharmaceuticals include Bristol-Myers Squibb, Versant Ventures, Prospect Venture Partners, Avalon Ventures and Novo Holdings.
Who are Amira Pharmaceuticals's competitors?
Competitors of Amira Pharmaceuticals include Vitae Pharmaceuticals, ISTA Pharmaceuticals, Nanomed Pharmaceuticals, Resolvyx Pharmaceuticals, Nitec Pharma and 13 more.
Compare Amira Pharmaceuticals to Competitors
Resolvyx Pharmaceuticals offers CombinatoRx which is creating new combination medicines that attack disease on multiple fronts
Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.
PetMedicus Labs is developing FDA-approved pharmaceuticals for the companion animal market.
Inflabloc Pharmaceuticals, Inc. is engaged in the research and development of pharmaceutical treatments for inflammatory disorders. Inflabloc's current product development is based on its discoveries of strong anti-inflammatory properties of dehydroepiandrosterone (DHEA), a steroid that is produced in the adrenal gland. The company's lead product line is a DHEA combination treatment. The company has 4 products in development. IP-1001 is slated to enter Phase 2 clinical trials in Crohn's disease later this year. IP-1002 has completed Phase 1. IP-1003 recently established proof-of-concept in an inflammatory bowel disease (IBD) animal model, while IP-1005 has just entered proof-of-concept testing in a C-reactive protein (CRP) mouse model.
Azevan Pharmaceuticals is a clinical stage, small molecule drug development company developing novel therapeutics to treat disorders of stress, mood, and behavior. The Company's first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and Major Depression. Vasopressin receptor antagonists represent a novel mechanism of action for addressing these indications.
Zebra Pharmaceuticals offers customized health products through nature and science.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.